山东三元生物科技股份有限公司 投资者关系活动记录表 编号：2025-003 |  | 特定对象调研 分析师会议 | □ | | | --- | --- | --- | --- | | □ 投资者关系活动 | 媒体采访 | □ | 业绩说明会 | | □ 类别 | 新闻发布会 | □ | 路演活动 | | □ | 现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | | | | 上海万纳私募基金管理有限公司杨君弈；中信建投证券股份有限 | | | | | 公司夏克扎提·努力木、杨骥、高畅；和谐健康保险股份有限公 | | | | | 司毛一鹏；平安理财有限责任公司芶思雨；招银国际资产管理有 | | | | | 限公司张慎平；华夏理财有限责任公司何煦；广东正圆私募基金 | | | | | 管理有限公司侯昭慧；中信建投经管委财富管理部客户裘峥、赖 | | | | | 昕；北京坤溪私募基金管理有限公司李任翾；长安汇通集团有限 | | | | | 责任公司李郑浩峰；博道基金管理有限公司陈磊；上海渊泓投资 | | | | | 管理有限公司顾屹泉；淳厚基金管理有限公司顾伟；深圳安瑞置 | | | | 参 ...

Core Viewpoint - The main investment logic driving the agricultural sector in 2026 will be both cyclical and growth perspectives, with an expectation of accelerated capacity reduction in the first half of 2026 and a potential upward trend in pig prices [1] Group 1: Cyclical Perspective - In the context of market losses and administrative capacity reduction, capacity deconstruction may accelerate in the fourth quarter of 2025 and the first half of 2026 [1] - The pig price is expected to fluctuate upwards in 2026 [1] - Companies with leading operational capabilities in the livestock and poultry industry chain are continuously recommended [1] Group 2: Growth Perspective - The domestic demand for the pet sector remains robust, with strong momentum for domestic brands, potentially leading to high growth in performance in the second half of 2026 [1] - In the fruit and vegetable planting sector, the blueberry dividend is expected to continue, with a focus on leading blueberry companies that are increasing planting area, improving planting efficiency, enhancing brand and channel development, and accelerating overseas expansion [1] - The functional sugar sector is anticipated to welcome a super single product in the sugar substitute category [1]

Core Viewpoint - The report from CITIC Securities suggests that in 2026, both cyclical and growth factors will drive the main investment logic in the agricultural sector [1] Group 1: Cyclical Perspective - Due to market losses and administrative capacity reduction, capacity deconstruction may accelerate in Q4 2025 and the first half of 2026, leading to a potential upward fluctuation in pig prices in 2026 [1] - The report continues to recommend companies in the livestock and poultry industry that demonstrate strong operational capabilities and can withstand cyclical fluctuations [1] Group 2: Growth Perspective - The domestic demand for the pet sector remains robust, with strong momentum for domestic brands, potentially leading to high growth in H2 2026 [1] - In the fruit and vegetable planting sector, the blueberry market is expected to continue benefiting from ongoing advantages, with a focus on leading companies that are increasing planting area, improving planting efficiency, enhancing brand and channel development, and accelerating international expansion [1] - The functional sugar sector is anticipated to welcome a super sugar substitute product [1]

Core Viewpoint - The resignation of Dai Sijue as the chairman of Baolingbao (stock code: 002286) due to personal reasons raises questions about the company's leadership during a challenging market period for erythritol products [1][3]. Company Summary - Dai Sijue submitted his resignation as chairman, director, and head of the board's strategic committee on November 17 [1]. - As of the announcement date, Dai held no direct shares in the company but controlled 29,508,653 shares (7.75% of total shares) through Beijing Yongyu Investment Management Co., Ltd., making him one of the actual controllers of the company [3]. - Beijing Yongyu Investment Management Co., Ltd. was listed as a dishonest executor by Jiangxi Bank with an execution target amount of 253 million yuan [3]. - Dai Sijue became the youngest chairman of an A-share company in 2021, taking office during a favorable period for the erythritol industry driven by the popularity of sugar-free beverages [3][5]. Industry Summary - Baolingbao is a leading company in the erythritol sector, which experienced rapid growth due to collaborations with popular brands like Yuanqi Forest [5]. - The erythritol market has faced challenges due to increased competition leading to oversupply and price wars [5]. - In November 2023, the European Commission initiated an anti-dumping investigation into erythritol products originating from China, adding pressure to the industry [5]. - Despite these challenges, Baolingbao reported a net profit of 111 million yuan for 2024, a year-on-year increase of 105.97%, attributing this success to improved supply chain management and a focus on high-value products [5]. - For the first three quarters of 2025, Baolingbao achieved a revenue of 2.126 billion yuan, a 15.98% increase year-on-year, and a net profit of 134 million yuan, up 32.58% year-on-year [5].

Core Points - The resignation of Dai Sijue, the chairman of Baolingbao, comes at a time when the company is experiencing a strong performance rebound, with a reported net profit of 1.11 billion yuan in 2024, a year-on-year increase of 105.97% [4] - Despite the company's recovery, Dai Sijue cited "personal reasons" for his resignation, which raises concerns about potential financial pressures within the controlling shareholder's structure [2][4] - The company has faced challenges, including a significant increase in competition and a price war in the erythritol industry, as well as an anti-dumping investigation by the European Union [4][6] Company Performance - Baolingbao reported a net profit of 1.11 billion yuan in 2024, marking a 105.97% increase year-on-year, with a significant rise in non-recurring net profit by 254.56% [4] - For the first three quarters of 2025, the company achieved a revenue of 2.126 billion yuan, a year-on-year growth of 15.98%, and a net profit of 134 million yuan, up 32.58% [4] - The growth is attributed to increased sales of core products such as sugar-reduced sweeteners, prebiotics, and dietary fibers, along with improved gross margins due to cost reduction and efficiency enhancements [4] Shareholder Dynamics - The actual control of Baolingbao shifted from Dai Sijue alone to a joint control structure with his brother, Dai Sicong, in August 2024 [6] - A promised shareholding increase by the new controlling entity has faced delays, with the initial commitment to increase holdings by at least 5% not being met due to "funding arrangements" [7] - As of the resignation announcement, Dai Sijue held 29.51 million shares through his investment company, representing 7.75% of the total share capital [7]

Core Viewpoint - The resignation of Dai Sijue, the chairman of Baolingbao, comes at a time of strong performance recovery for the company, raising questions about underlying financial pressures within the controlling shareholder's structure [5][6]. Company Overview - Baolingbao's stock price was reported at 10.86 yuan, with a market capitalization of 4.064 billion yuan as of November 17 [2]. - Dai Sijue, born in January 1995, became the youngest chairman in A-share market history at the age of 26 in March 2021 [3][6]. - His tenure lasted approximately four and a half years, during which he faced significant challenges, including industry fluctuations and an EU anti-dumping investigation [4][6]. Performance Analysis - Despite the challenges, Baolingbao demonstrated resilience, achieving a net profit of 111 million yuan in 2024, a year-on-year increase of 105.97%, and a significant rise in net profit excluding non-recurring items by 254.56% [8]. - For the first three quarters of 2025, the company reported revenue of 2.126 billion yuan, up 15.98%, and a net profit of 134 million yuan, reflecting a 32.58% increase year-on-year [8]. Shareholder Dynamics - The actual control of Baolingbao shifted in August 2024 from Dai Sijue alone to a joint control structure with his brother, Dai Sicong [10]. - A planned share buyback by the new controlling entity has faced delays due to "funding arrangements," with the initial commitment to increase holdings by 5% not being met [11][12]. - As of the resignation announcement, Dai Sijue held 29.5087 million shares through his investment firm, representing 7.75% of the total shares [13].

Core Viewpoint - The resignation of Dai Sijue, the youngest chairman in A-share history, comes at a time when the company, Baolingbao, is experiencing a strong performance rebound, raising questions about underlying pressures within the company's control structure [1][2][3] Company Performance - Baolingbao reported a net profit of 111 million yuan for 2024, a year-on-year increase of 105.97%, and a significant increase in non-recurring net profit by 254.56% [3] - For the first three quarters of 2025, Baolingbao achieved a revenue of 2.126 billion yuan, up 15.98% year-on-year, and a net profit of 134 million yuan, reflecting a 32.58% increase [3] Industry Context - The erythritol industry faced severe supply-demand imbalances and price wars in 2023 due to an influx of new players, followed by an anti-dumping investigation by the European Union [3] - The company has shown resilience in navigating the industry's cyclical challenges, focusing on high-value products and optimizing supply chain management [3] Control Structure Changes - The actual control of Baolingbao shifted from Dai Sijue alone to a joint control with his brother, Dai Sicong, in August 2024 [5] - A promised share buyback plan by the new controlling entity has faced delays, with the initial commitment to increase holdings by 5% not being fulfilled as of the latest reports [6] Financial Pressures - Dai Sijue's controlling entity, Yongyu Investment, has faced significant financial pressures, being listed as an executor in multiple court cases with total amounts exceeding 280 million yuan [1][6] - As of the resignation announcement, Dai Sijue held 7.75% of Baolingbao's shares through Yongyu Investment, indicating ongoing involvement despite his resignation [6]

Core Viewpoint - The resignation of Dai Sijue, the youngest chairman in A-share history, comes amid a strong performance rebound for Baolingbao, raising questions about underlying financial pressures within the company's controlling entities [1][2][3] Group 1: Resignation Details - Dai Sijue submitted his resignation as chairman and board member of Baolingbao on November 17, 2023, citing personal reasons [2] - He will continue to hold positions in Baolingbao's subsidiaries, indicating a partial retention of influence [2] - Dai Sijue became chairman in March 2021 at the age of 26, during a peak period for the sugar-free beverage market [2][3] Group 2: Company Performance - Baolingbao reported a net profit of 111 million yuan for 2024, a year-on-year increase of 105.97%, and a significant rise in non-recurring net profit by 254.56% [3] - For the first three quarters of 2025, the company achieved a revenue of 2.126 billion yuan, up 15.98%, and a net profit of 134 million yuan, reflecting a 32.58% increase [3] - The growth is attributed to increased sales of core products such as sugar-reduced sweeteners and dietary fibers, alongside improved gross margins [3] Group 3: Control and Financial Pressures - The actual control of Baolingbao shifted from Dai Sijue alone to a joint control with his brother, Dai Sicong, in August 2024 [4] - A planned share buyback by Dai Sicong's investment firm has faced delays due to "funding arrangements," with the initial commitment to acquire 5% of shares not met [4][5] - Dai Sijue's investment firm, Yongyu Investment, has been listed as a defendant in multiple court cases, with total amounts exceeding 280 million yuan, indicating financial strain [1][5]

Core Viewpoint - The report from Huaxi Securities indicates that Baolingbao's Q3 2025 revenue, net profit attributable to shareholders, and net profit excluding non-recurring items were 727 million, 41 million, and 34 million yuan respectively, showing year-on-year growth of 12.23%, 30.21%, and 11.72% [1] Group 1: Financial Performance - Baolingbao's significant revenue growth is attributed to the substantial increase in sales of core products such as sugar-reducing sweeteners, prebiotics, and dietary fibers [1] - The improvement in gross margin is due to cost reduction and efficiency enhancement, alongside the increasing revenue share from core products [1] Group 2: Market Position and Product Strategy - As a leading enterprise in the domestic functional sugar industry, Baolingbao holds a significant market share in sugar-reducing sweeteners, prebiotics, and dietary fibers, supported by its comprehensive product layout and technological advantages [1] Group 3: Future Outlook - Short-term: With the new corn harvest in major production areas, corn prices are expected to remain low in Q4, which, combined with production cost reductions, may further enhance the gross margin of core products [1] - Mid-term: The accelerated approval process for allulose in China is expected to open up the domestic market, with Baolingbao's 20,000-ton expansion project already initiated, aiming for an annual capacity of approximately 30,000 tons by the end of 2026 [1] - Long-term: The launch of new high-value-added products such as HMOs (human milk oligosaccharides), algal oil DHA, and sugar-free resistant dextrin will further optimize the company's profit structure [1]

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company's revenue, net profit attributable to shareholders, and net profit after deducting non-recurring gains and losses for Q3 2025 were CNY 727 million, CNY 41 million, and CNY 34 million, respectively, representing year-on-year growth of 12.23%, 30.21%, and 11.72% [2] - The significant growth in performance is attributed to the substantial increase in sales of core products such as sugar-reduced sweeteners, prebiotics, and dietary fibers, along with improved gross margins due to cost reduction and efficiency enhancement [2][3] - The company's three core products accounted for 61.5% of revenue, with a gross margin contribution of 68.6%, and their sales revenue grew by 25.8% year-on-year [3] - The approval of HMO (Human Milk Oligosaccharides) for infant formula has been finalized, allowing for the expansion of product offerings in this category [4] - The gross margin for Q3 2025 was 13.54%, an increase of 1.76 percentage points year-on-year, while the gross margin for core products improved by 5.3 percentage points [5] Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported revenue of CNY 2.126 billion, net profit attributable to shareholders of CNY 134 million, and operating cash flow of CNY 158 million, reflecting year-on-year growth of 15.98%, 32.58%, and 62.38% respectively [2] - The company’s inventory decreased by 8.06% year-on-year, with inventory turnover days reduced to 39 days [6] Investment Recommendations - The company is positioned as a leader in the functional sugar industry, with a strong market share in sugar-reduced sweeteners, prebiotics, and dietary fibers [7] - Short-term outlook suggests further improvement in gross margins due to declining corn prices and production efficiency [7] - Mid-term prospects include accelerated approval for allulose, which is expected to open up the domestic market [7] - Long-term growth is anticipated from the launch of high-value products such as HMOs, DHA, and sugar-free resistant dextrin [7] Financial Projections - Revenue projections for 2025, 2026, and 2027 are CNY 2.718 billion, CNY 2.966 billion, and CNY 3.211 billion, respectively, with corresponding net profits of CNY 179 million, CNY 222 million, and CNY 269 million [9][11]